HMGB1: a Multifunctional Alarmin Driving Autoimmune and Inflammatory Disease

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2012 Feb 2

PMID 22293756

Citations 356

Authors

Helena Erlandsson Harris

Ulf Andersson

David S Pisetsky

Affiliations

Soon will be listed here.

Abstract

HMGB1 is a non-histone nuclear protein that can serve as an alarmin to drive the pathogenesis of inflammatory and autoimmune disease. Although primarily located in the cell nucleus, HMGB1 can translocate to the cytoplasm, as well as the extracellular space, during cell activation and cell death; during activation, HMGB1 can undergo post-translational modifications. The activity of HMGB1 varies with the redox states of the cysteine residues, which are required for binding to TLR4. In addition to stimulating cells directly, HMGB1 can form immunostimulatory complexes with cytokines and other endogenous and exogenous factors. In the synovia of patients with rheumatoid arthritis, as well as animal models of this disease, extranuclear expression of HMGB1 is increased and blockade of HMGB1 expression attenuates disease in animal models. In systemic lupus erythematosus, HMGB1 can be a component of immune complexes containing anti-DNA because of its interaction with DNA. In myositis, expression of HMGB1 is enhanced in inflamed muscle and can perturb muscle function. Together, these findings indicate that HMGB1 might be an important mediator and biomarker in rheumatic diseases as well as a target of new therapy.

Citing Articles

New Insights on Childhood Lupus Nephritis.

Marchi-Silva R, De Aquino B, Londe A, Mazzola T, Julio P, Wampler Muskardin T Int J Nephrol Renovasc Dis. 2025; 18():1-12.

PMID: 39829960 PMC: 11740589. DOI: 10.2147/IJNRD.S405789.

Dual alarmin-receptor-specific targeting peptide systems for treatment of sepsis.

Mun S, Cho E, Gil W, Kim S, Kim H, Ham Y Acta Pharm Sin B. 2025; 14(12):5451-5463.

PMID: 39807314 PMC: 11725134. DOI: 10.1016/j.apsb.2024.08.015.

Roles of the Receptor for Advanced Glycation End Products and Its Ligands in the Pathogenesis of Alzheimer's Disease.

Li W, Chen Q, Peng C, Yang D, Liu S, Lv Y Int J Mol Sci. 2025; 26(1.

PMID: 39796257 PMC: 11721675. DOI: 10.3390/ijms26010403.

Cardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction.

Qin D, Wang X, Pu J, Hu H Front Cardiovasc Med. 2025; 11:1493290.

PMID: 39744211 PMC: 11688320. DOI: 10.3389/fcvm.2024.1493290.

Exploratory Research for HIF-1α Overexpression Tumor Antigen in the Activation of Dendritic Cells and the Potent Anti-Tumor Immune Response.

Zhao J, Zhang H, Zhao Y, Lin Z, Lin F, Wang Z Cancer Manag Res. 2024; 16:1813-1822.

PMID: 39713567 PMC: 11662640. DOI: 10.2147/CMAR.S482363.

References

Kazama H, Ricci J, Herndon J, Hoppe G, Green D, Ferguson T . Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 2008; 29(1):21-32. PMC: 2704496. DOI: 10.1016/j.immuni.2008.05.013. View

Ma C, Jiao Y, Zhang J, Yang Q, Zhang Z, Shen Y . Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus. Rheumatol Int. 2010; 32(2):395-402. DOI: 10.1007/s00296-010-1636-6. View

Kokkola R, Li J, Sundberg E, Aveberger A, Palmblad K, Yang H . Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003; 48(7):2052-8. DOI: 10.1002/art.11161. View

Goldstein R, Bruchfeld A, Yang L, Qureshi A, Gallowitsch-Puerta M, Patel N . Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med. 2007; 13(3-4):210-5. PMC: 1899837. DOI: 10.2119/2006–00108.Goldstein. View

Pullerits R, Urbonaviciute V, Voll R, Forsblad-dElia H, Carlsten H . Serum levels of HMGB1 in postmenopausal patients with rheumatoid arthritis: associations with proinflammatory cytokines, acute-phase reactants, and clinical disease characteristics. J Rheumatol. 2011; 38(7):1523-5. DOI: 10.3899/jrheum.110091. View

Urbonaviciute V, Furnrohr B, Meister S, Munoz L, Heyder P, De Marchis F . Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008; 205(13):3007-18. PMC: 2605236. DOI: 10.1084/jem.20081165. View

Nickel W, Rabouille C . Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol. 2009; 10(2):148-55. DOI: 10.1038/nrm2617. View

Wahamaa H, Schierbeck H, Hreggvidsdottir H, Palmblad K, Aveberger A, Andersson U . High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther. 2011; 13(4):R136. PMC: 3239379. DOI: 10.1186/ar3450. View

Agresti A, Lupo R, Bianchi M, Muller S . HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun. 2003; 302(2):421-6. DOI: 10.1016/s0006-291x(03)00184-0. View

10.

Ivanov S, Dragoi A, Wang X, Dallacosta C, Louten J, Musco G . A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007; 110(6):1970-81. PMC: 1976374. DOI: 10.1182/blood-2006-09-044776. View

11.

Barkauskaite V, Ek M, Popovic K, Harris H, Wahren-Herlenius M, Nyberg F . Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus. 2007; 16(10):794-802. DOI: 10.1177/0961203307081895. View

12.

Gaillard C, Borde C, Gozlan J, Marechal V, Strauss F . A high-sensitivity method for detection and measurement of HMGB1 protein concentration by high-affinity binding to DNA hemicatenanes. PLoS One. 2008; 3(8):e2855. PMC: 2478715. DOI: 10.1371/journal.pone.0002855. View

13.

Wittemann B, Neuer G, Michels H, Truckenbrodt H, BAUTZ F . Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1990; 33(9):1378-83. DOI: 10.1002/art.1780330910. View

14.

Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M . High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003; 48(4):971-81. DOI: 10.1002/art.10859. View

15.

Hoshina T, Kusuhara K, Ikeda K, Mizuno Y, Saito M, Hara T . High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scand J Rheumatol. 2008; 37(6):445-9. DOI: 10.1080/03009740802144143. View

16.

Kokkola R, Sundberg E, Ulfgren A, Palmblad K, Li J, Wang H . High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002; 46(10):2598-603. DOI: 10.1002/art.10540. View

17.

Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T . Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 2008; 58(9):2675-85. DOI: 10.1002/art.23729. View

18.

Li J, Xie H, Wen T, Liu H, Zhu W, Chen X . Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol. 2010; 37(4):766-75. DOI: 10.3899/jrheum.090663. View

19.

Hofmann M, Drury S, Hudson B, Gleason M, Qu W, Lu Y . RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002; 3(3):123-35. DOI: 10.1038/sj.gene.6363861. View

20.

Andersson U, Tracey K . HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. PMC: 4536551. DOI: 10.1146/annurev-immunol-030409-101323. View